| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
| Targets |
CXCR7 antagonist-1 targets CXCR7 (also known as ACKR3), a chemokine receptor that binds SDF-1 (CXCL12) and I-TAC (CXCL11). CXCR7 is involved in cell migration, proliferation, and survival, and is overexpressed in various cancers. By antagonizing CXCR7, CXCR7 antagonist-1 blocks the binding of its ligands and inhibits downstream signaling pathways.
|
|---|---|
| ln Vitro |
In vitro, CXCR7 antagonist-1 inhibits the binding of SDF-1 or I-TAC to CXCR7. It prevents tumor cell proliferation and tumor formation. CXCR7 antagonist-1 is useful in preventing tumor cell proliferation, tumor formation, inflammatory diseases, and many other diseases.
|
| ln Vivo |
In vivo data for CXCR7 antagonist-1 is not extensively reported in publicly available sources. As a CXCR7 antagonist, the compound has potential applications in animal models of cancer and inflammatory diseases. By blocking CXCR7 signaling, CXCR7 antagonist-1 could inhibit tumor growth and inflammation. However, specific published in vivo efficacy studies are not detailed in the current literature.
|
| Enzyme Assay |
The in vitro CXCR7 binding assay for CXCR7 antagonist-1 uses cells expressing CXCR7 and labeled SDF-1 or I-TAC. Binding affinity is measured by quantifying the displacement of the labeled ligand. IC50 values are calculated from dose-response curves. Cell proliferation is assessed in cancer cell lines using standard cell viability assays.
|
| Cell Assay |
Cellular assays for CXCR7 antagonist-1 are conducted in cancer cell lines and immune cells. Cells are treated with varying concentrations of CXCR7 antagonist-1. Cell proliferation and viability are measured using standard assays such as MTT or CellTiter-Glo. Cell migration is assessed using transwell assays. Signaling pathways downstream of CXCR7 are assessed by Western blotting.
|
| Animal Protocol |
In vivo studies for CXCR7 antagonist-1 would typically involve xenograft mouse models of cancer or models of inflammatory diseases. The compound would be administered via intraperitoneal or oral routes. Efficacy would be assessed by measuring tumor growth inhibition or inflammatory markers. However, specific published in vivo protocols for CXCR7 antagonist-1 are not available in the current literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for CXCR7 antagonist-1 is not extensively reported. The compound has a molecular weight of 390.41 g/mol and a molecular formula of C21H19FN6O. It has a CAS number of 1613021-99-0. As a small molecule, it is expected to have moderate bioavailability. Detailed PK parameters such as half-life and bioavailability are not available.
|
| Toxicity/Toxicokinetics |
Toxicity data for CXCR7 antagonist-1 is limited. As a research compound, CXCR7 antagonist-1 is intended for research use only and not for human therapeutic applications. Standard in vitro cytotoxicity assays and in vivo tolerability studies would be required for a complete toxicity assessment.
|
| References | |
| Additional Infomation |
CXCR7 antagonist-1 (CAS 1613021-99-0) is a specific antagonist of CXCR7 that inhibits SDF-1 or I-TAC binding. It prevents tumor cell proliferation and tumor formation. It has a molecular formula of C21H19FN6O and a molecular weight of 390.41 g/mol. CXCR7 antagonist-1 is for research use only.
|
| Molecular Formula |
C21H19FN6O
|
|---|---|
| Molecular Weight |
390.41
|
| Exact Mass |
390.16
|
| CAS # |
1613021-99-0
|
| Related CAS # |
CXCR7 antagonist-1 hydrochloride
|
| PubChem CID |
90192074
|
| Appearance |
Off-white to gray solid powder
|
| LogP |
3.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
29
|
| Complexity |
586
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
N1(C2=CC=C(F)C=C2)C=CC(C(N[C@H]2CCN(C3=NC=CN4C=CC=C34)C2)=O)=N1
|
| InChi Key |
IGJCDMUXCOCMMI-INIZCTEOSA-N
|
| InChi Code |
InChI=1S/C21H19FN6O/c22-15-3-5-17(6-4-15)28-12-8-18(25-28)21(29)24-16-7-11-27(14-16)20-19-2-1-10-26(19)13-9-23-20/h1-6,8-10,12-13,16H,7,11,14H2,(H,24,29)/t16-/m0/s1
|
| Chemical Name |
1-(4-fluorophenyl)-N-[(3S)-1-pyrrolo[1,2-a]pyrazin-1-ylpyrrolidin-3-yl]pyrazole-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~256.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5614 mL | 12.8070 mL | 25.6141 mL | |
| 5 mM | 0.5123 mL | 2.5614 mL | 5.1228 mL | |
| 10 mM | 0.2561 mL | 1.2807 mL | 2.5614 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
